Considering advanced EGFR-mutant NSCLC, the phase III FLAURA2 trial tested first-line osimertinib plus platinum–pemetrexed versus solo osimertinib in treatment-naïve [38]. Here, EGFR is linked to non-small cell lung carcinoma.